<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.0 20040830//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Histopathology</journal-id><journal-id journal-id-type="publisher-id">his</journal-id><journal-title-group><journal-title>Histopathology</journal-title></journal-title-group><issn pub-type="ppub">0309-0167</issn><issn pub-type="epub">1365-2559</issn><publisher><publisher-name>Blackwell Publishing Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.1111/j.1365-2559.2009.03399.x</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Histogenesis-specific expression of fibroblast activation protein and dipeptidylpeptidase-IV in human bone and soft tissue tumours</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Dohi</surname><given-names>Osamu</given-names></name><xref ref-type="aff" rid="au1">1</xref><xref ref-type="aff" rid="au2">2</xref><xref ref-type="aff" rid="au3">3</xref></contrib><contrib contrib-type="author"><name><surname>Ohtani</surname><given-names>Haruo</given-names></name><xref ref-type="aff" rid="au4">4</xref></contrib><contrib contrib-type="author"><name><surname>Hatori</surname><given-names>Masahito</given-names></name><xref ref-type="aff" rid="au1">1</xref></contrib><contrib contrib-type="author"><name><surname>Sato</surname><given-names>Elichi</given-names></name><xref ref-type="aff" rid="au2">2</xref></contrib><contrib contrib-type="author"><name><surname>Hosaka</surname><given-names>Masami</given-names></name><xref ref-type="aff" rid="au1">1</xref></contrib><contrib contrib-type="author"><name><surname>Nagura</surname><given-names>Hiroshi</given-names></name><xref ref-type="aff" rid="au2">2</xref></contrib><contrib contrib-type="author"><name><surname>Itoi</surname><given-names>Eiji</given-names></name><xref ref-type="aff" rid="au1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kokubun</surname><given-names>Shoichi</given-names></name><xref ref-type="aff" rid="au1">1</xref></contrib><aff id="au1"><label>1</label><institution>Departments of Orthopaedic Surgery, Tohoku University Graduate School of Medicine</institution><addr-line>Mito, Japan</addr-line></aff><aff id="au2"><label>2</label><institution>Departments of Pathology, Tohoku University Graduate School of Medicine</institution><addr-line>Mito, Japan</addr-line></aff><aff id="au3"><label>3</label><institution>Department of Orthopaedic Surgery, Tohoku Kosai Hospital, Sendai</institution><addr-line>Mito, Japan</addr-line></aff><aff id="au4"><label>4</label><institution>Department of Pathology, Mito Medical Centre, National Hospital Organization</institution><addr-line>Mito, Japan</addr-line></aff></contrib-group><author-notes><corresp id="cor1">Address for correspondence: M Hatori, Department of Orthopaedic Surgery, Tohoku University Graduate School of Medicine, 1-1, Seiryomachi, Aoba-ku, Sendai 980-8574, Japan. e-mail: <email>mhato@mail.tains.tohoku.ac.jp</email> and H Ohtani, Department of Pathology, Mito Medical Centre, National Hospital Organization, Mito 311-3193, Japan. e-mail: <email>hohtani@mito.hosp.go.jp</email>.</corresp><fn fn-type="present-address"><p>Present address: E Sato, Department of Pathology, Tokyo Medical University, Shinjuku, Tokyo, Japan.</p></fn><fn><p>Dohi O, Ohtani H, Hatori M, Sato E, Hosaka M, Nagura H, Itoi E &#x00026; Kokubun S (2009) <italic>Histopathology</italic><bold>55,</bold> 432&#x02013;440</p><p><bold>Histogenesis-specific expression of fibroblast activation protein and dipeptidylpeptidase-IV in human bone and soft tissue tumours</bold></p></fn></author-notes><pub-date pub-type="ppub"><month>10</month><year>2009</year></pub-date><volume>55</volume><issue>4</issue><fpage>432</fpage><lpage>440</lpage><history><date date-type="received"><day>28</day><month>7</month><year>2008</year></date><date date-type="accepted"><day>02</day><month>3</month><year>2009</year></date></history><permissions><copyright-statement>Journal compilation &#x000a9; 2009 Blackwell Publishing Ltd</copyright-statement><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.5/"><license-p>Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation.</license-p></license></permissions><abstract><sec><title>Aims:</title><p>Fibroblast activation protein (FAP)/seprase and dipeptidylpeptidase-IV (DPP-IV)/CD26 are serine integral membrane proteases. They are involved in tissue remodelling, cancer invasion and metastases, mechanisms that are controversial. The aim was to identify cell types that express FAP and DPP-IV in human bone and soft tissue tumours, and to determine whether there are any correlations between the expression of FAP and DPP-IV and the malignant potential of tumours.</p></sec><sec><title>Methods and results:</title><p>This study analysed <italic>in situ</italic> expression in 25 malignant and 13 benign human bone and soft tissue tumours. Reverse transcriptase-polymerase chain reaction analyses confirmed mRNA expression of FAP and DPP-IV in all individuals. Immunohistochemistry using pre-fixed frozen sections revealed that FAP was positive in low-grade myofibroblastic sarcoma, the fibroblastic component of osteosarcomas, and malignant fibrous histiocytomas, but negative in Ewing&#x02019;s sarcomas and rhabdomyosarcomas. DPP-IV showed similar immunohistochemical results. Among benign tumours, non-ossifying fibromas, desmoid tumours and chondroblastomas expressed both FAP and DPP-IV. Giant cells expressed DPP-IV in giant cell tumours.</p></sec><sec><title>Conclusions:</title><p>Our data suggest that FAP and DPP-IV are consistently expressed in bone and soft tissue tumour cells that are histogenetically related to activated fibroblasts and/or myofibroblasts, irrespective of their malignancy. DPP-IV is also expressed in monocyte&#x02013;macrophage lineage cells.</p></sec></abstract><kwd-group><kwd>bone and soft tissue tumours</kwd><kwd>dipeptidylpeptidase-IV</kwd><kwd>fibroblast activation protein</kwd><kwd>histogenesis</kwd><kwd>human</kwd></kwd-group></article-meta></front><body><sec><title>Introduction</title><p>Fibroblast activation protein (FAP)/seprase is a serine integral membrane proteinase. The molecular weight of FAP is either 95 or 97 kDa as a monomer and 170 kDa as a dimer. The dimer shows gelatinolytic activity.<xref ref-type="bibr" rid="b1">1</xref>,<xref ref-type="bibr" rid="b2">2</xref> FAP is reported as an antigen that is recognized by antibody F19.<xref ref-type="bibr" rid="b3">3</xref>,<xref ref-type="bibr" rid="b4">4</xref> FAP is not expressed in normal fibroblasts or smooth muscle cells in adults, although strongly expressed in activated fibroblasts,<xref ref-type="bibr" rid="b5">5</xref>&#x02013;<xref ref-type="bibr" rid="b8">8</xref> including stromal fibroblasts in human cancers<xref ref-type="bibr" rid="b9">9</xref> and granulation tissue associated with wound healing.<xref ref-type="bibr" rid="b1">1</xref> Dipeptidylpeptidase-IV (DPP-IV)/CD26 has a molecular weight of 105 kDa and is also a serine integral membrane proteinase. It is an activation antigen of T lymphocytes. It is diffusely positive in cells of the proximal tubules of the kidney, small intestinal mucosa, bile ducts, sinusoidal lining cells of the spleen, subsets of vascular endothelial cells and fibroblasts.<xref ref-type="bibr" rid="b7">7</xref> Since FAP and DPP-IV are both serine proteases, attention has focused on their potential to promote cancer cell invasion and metastasis, although the results of such studies are controversial.<xref ref-type="bibr" rid="b7">7</xref>,<xref ref-type="bibr" rid="b10">10</xref>&#x02013;<xref ref-type="bibr" rid="b13">13</xref> Both FAP and DPP-IV are abundantly expressed in the stroma of &#x0003e;90% of breast, colorectal and lung carcinomas.<xref ref-type="bibr" rid="b7">7</xref>,<xref ref-type="bibr" rid="b14">14</xref>,<xref ref-type="bibr" rid="b15">15</xref> FAP and DPP-IV are also expressed in sarcomas.<xref ref-type="bibr" rid="b7">7</xref> However, detailed cell identification has not been performed for these two proteases in sarcomatous tissues. Furthermore, the relationship between the expression of these two proteinases and the malignancy of tumours has not been clarified.</p><p>The present study was designed to identify cell types that express FAP and DPP-IV in human bone and soft tissue tumours, and to determine whether there are any correlations between the expression of FAP and DPP-IV and the malignant potential of tumours.</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><p>Forty-one bone and soft tissue tumours were analysed. All specimens were obtained by open biopsy or surgical resection from patients, none of whom had received radiation or chemotherapy. All tumours were diagnosed on the basis of clinical features, imaging, conventional histopathology and immunohistochemistry of paraffin-embedded sections. There were 26 malignant and 15 benign tumours: 11 osteosarcomas (eight osteoblastic, two fibroblastic, one chondroblastic), four Ewing&#x02019;s sarcomas, four malignant fibrous histiocytomas (MFH) of pleomorphic type (undifferentiated high-grade pleomorphic sarcoma), two rhabdomyosarcomas, two low-grade myofibroblastic sarcomas,<xref ref-type="bibr" rid="b16">16</xref> one adamantinoma, four giant cell tumours, three schwannomas, one non-ossifying fibroma, one osteoid osteoma, one desmoid tumour, one chondroblastoma, one lipoma, and one elastofibroma. Fibrous granulation tissue obtained from four decubitus ulcers were used as positive controls.<xref ref-type="bibr" rid="b7">7</xref> Soft tissues without tumour invasion were used as normal controls, which were removed with the sarcomas. Of these, the two cases of low-grade myofibroblastic sarcoma were originally diagnosed as &#x02018;leiomyosarcoma&#x02019;. The reasons for the change of diagnosis included (i) expression of smooth muscle actin is common to low-grade myofibroblastic sarcoma and leiomyosarcoma, and (ii) the tumour cells in the two cases lacked enhanced cytoplasmic eosinophilia or blunt-ended nuclei, and did not express calponin on immunohistochemistry.<xref ref-type="bibr" rid="b17">17</xref>,<xref ref-type="bibr" rid="b18">18</xref></p><p>mRNA analyses were performed on all specimens according to the method described by Katou <italic>et al.</italic><xref ref-type="bibr" rid="b19">19</xref> The primer sequences were as follows: FAP: +5-GCTAACTTTCAAAAACATCTGGAAAAATG-3 (sense) and +5-GTAATATGTTGCTGTGTAAGAGTATCTCC-3 (anti-sense), and DPP-IV: +5-CTAACTGGACTGGTTCAAATGTTGT-3 (sense) and +5-CAGGGCAAGCTGATGTGTTCACATCTC-3 (anti-sense).</p><p>For immunohistochemistry, specimens were fixed in periodate&#x02013;lysine 4% paraformaldehyde for 6&#x02013;8 h at 4&#x000b0;C. After washing in phosphate-buffered saline, the fixed specimens were frozen. Primary antibodies were mouse monoclonal anti-FAP (clone F19),<xref ref-type="bibr" rid="b9">9</xref> rat monoclonal anti-FAP (clone D8)<xref ref-type="bibr" rid="b20">20</xref> and mouse monoclonal anti-DPP-IV (anti-CD26) (clone M-A261; Pharmingen, San Diego, CA, USA). Envision Plus was used as the secondary antibody (Dako, Tokyo, Japan). Isotype-matched control mouse monoclonal antibodies (Dako) were used as the negative control.</p><p>The US Food and Drug Administration-approved scoring system for HER2 protein was adopted for semiquantification of the localization patterns of FAP and DPP-IV because the immunoreactivity of both proteases along the cell membrane is similar to that of HER2.<xref ref-type="bibr" rid="b21">21</xref> In brief: score 0, negative or positive in &#x0003c;10% of tumour cells; score 1+, weakly positive in &#x0003e;10% of tumour cells; score 2+, moderately positive in &#x0003e;10% of tumour cells; and score 3+, strongly positive in &#x0003e;10% of tumour cells.</p></sec><sec><title>Results</title><sec><title>Confirmation of the expression of FAP and DPP-IV in sarcomatous tissue</title><p>Reverse transcriptase-polymerase chain reaction analyses identified the expression of mRNAs for both FAP and DPP-IV in all specimens examined (<xref ref-type="fig" rid="fig01">Figure 1</xref>). Direct sequencing confirmed the reaction products as FAP and DPP-IV by referring to the home page of the National Center for Biotechnology Information (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/">http://www.ncbi.nlm.nih.gov/</ext-link>) (Bethesda, MD, USA).</p><fig id="fig01" position="float"><label>Figure 1</label><caption><p>Results of reverse transcriptase-polymerase chain reaction analyses. Lanes: 1, low-grade myofibroblastic sarcoma (case 1); 2, low-grade myofibroblastic sarcoma (case 2); 3, Ewing&#x02019;s sarcoma; 4, osteosarcoma (a fibroblastic type); 5, osteosarcoma (osteoblastic type); 6, granulation tissue; 7, RNA(&#x02212;); and HKG, housekeeping gene.</p></caption><graphic xlink:href="his0055-0432-f1"/></fig></sec><sec><title>Both FAP and DPP-IV are expressed mainly in spindle-shaped cells</title><p>To identify the cell types, immunohistochemistry was performed using pre-fixed frozen sections, not conventional paraffin-embedded sections, in order to attain more reliable sensitivity, and the results analysed using the semiquantification method (<xref ref-type="table" rid="tbl1">Table 1</xref>). For malignant tumours, we analysed low-grade myofibroblastic sarcoma, osteosarcomas, MFH, rhabdomyosarcoma, Ewing&#x02019;s sarcoma, and adamantinoma. FAP and DPP-IV were strongly positive in both cases of low-grade myofibroblastic sarcoma, and the positive cells were uniformly spindle-shaped tumour cells (<xref ref-type="fig" rid="fig02">Figure 2</xref>). All of the 11 osteosarcomas also expressed FAP and DPP-IV. As summarized in <xref ref-type="table" rid="tbl1">Table 1</xref>, it is notable that positive cells for FAP and DPP-IV were observed specifically in fibroblastic areas (<xref ref-type="fig" rid="fig03">Figure 3</xref>), whereas they were sparse in osteoblastic (<xref ref-type="fig" rid="fig04">Figure 4</xref>) and chondroblastic areas. The positive cells in fibroblastic areas were spindle-shaped fibroblastic tumour cells. FAP and DPP-IV were also positive in fibroblastic tumour cells in two of four and four of four MFHs, respectively. In contrast, no tumour cells expressed FAP or DPP-IV in four Ewing&#x02019;s sarcomas, two rhabdomyosarcomas, or one adamantinoma. However, it should be noted that reactive fibroblasts in the fibrous septum of all four Ewing&#x02019;s sarcomas expressed FAP and DPP-IV moderately to weakly (<xref ref-type="fig" rid="fig05">Figure 5</xref>). In addition to fibroblastic cells, DPP-IV was also expressed in osteoclast-like giant cells in five of 11 osteosarcomas.</p><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><p>Results of immunohistochemistry</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" colspan="2" rowspan="1">Score<hr/></th></tr><tr><th align="center" rowspan="1" colspan="1">Diagnosis (number of cases)</th><th align="center" rowspan="1" colspan="1">Case</th><th align="center" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">FAP</th><th align="center" rowspan="1" colspan="1">DPP-IV</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">Low-grade myofibroblastic sarcoma (<italic>N</italic> = 2)</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">3</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">Osteosarcoma</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">F</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">2</td></tr><tr><td align="center" rowspan="1" colspan="1">Fibroblastic type (<italic>N</italic> = 2)</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">O</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">C</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">F</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">O</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">C</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="center" rowspan="1" colspan="1">Osteoblastic type (<italic>N</italic> = 8)</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">F</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">O</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">C</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">F</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">3</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">O</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">C</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">F</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">3</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">O</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">C</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">F</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">2</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">O</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">1</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">C</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">F</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">2</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">O</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">1</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">C</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">F</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">3</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">O</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">C</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">F</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">3</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">O</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">C</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">F</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">3</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">O</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">C</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="center" rowspan="1" colspan="1">Chondroblastic type (<italic>N</italic> = 1)</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">F</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">2</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">O</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">C</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="center" rowspan="1" colspan="1">Malignant fibrous histiocytoma (<italic>N</italic> = 4)</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">3</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">3</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">3</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">17</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">3</td></tr><tr><td align="center" rowspan="1" colspan="1">Rhabdomyosarcoma (<italic>N</italic> = 4)</td><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">19</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="center" rowspan="1" colspan="1">Ewing&#x02019;s sarcoma (<italic>N</italic> = 4)</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">22</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">23</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">Adamantinoma (<italic>N</italic> = 1)</td><td align="center" rowspan="1" colspan="1">24</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">Non-ossifying fibroma (<italic>N</italic> = 1)</td><td align="center" rowspan="1" colspan="1">26</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">3</td></tr><tr><td align="center" rowspan="1" colspan="1">Giant cell tumor (<italic>N</italic> = 4)</td><td align="center" rowspan="1" colspan="1">27</td><td align="center" rowspan="1" colspan="1">G</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">3</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">M</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">1</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">F</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">1</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">28</td><td align="center" rowspan="1" colspan="1">G</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">3</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">M</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">2</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">F</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">1</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">29</td><td align="center" rowspan="1" colspan="1">G</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">3</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">M</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">3</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">F</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">2</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">G</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">3</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">M</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">3</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">F</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">Desmoid (<italic>N</italic> = 1)</td><td align="center" rowspan="1" colspan="1">31</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">3</td></tr><tr><td align="left" rowspan="1" colspan="1">Chondroblastoma (<italic>N</italic> = 1)</td><td align="center" rowspan="1" colspan="1">32</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">2</td></tr><tr><td align="center" rowspan="1" colspan="1">Schwannoma (<italic>N</italic> = 3)</td><td align="center" rowspan="1" colspan="1">33</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">1</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">34</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">35</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">Lipoma (<italic>N</italic> = 1)</td><td align="center" rowspan="1" colspan="1">36</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">Elastofibroma (<italic>N</italic> = 1)</td><td align="center" rowspan="1" colspan="1">37</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">Osteoid osteoma (<italic>N</italic> = 1)</td><td align="center" rowspan="1" colspan="1">38</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">3</td></tr><tr><td align="left" rowspan="1" colspan="1">Granulation tissues</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">3</td></tr></tbody></table><table-wrap-foot><fn><p>Evaluation method for HER2 immunoreactivity was adopted for semiquantification. Pleomorphic malignant fibrous histiocytoma is also referred to as &#x02018;undifferentiated pleomorphic high-grade sarcoma&#x02019;.</p></fn><fn><p>F, fibroblastic area; O, osteoblastic area; C, chondroblastic area; G, giant cells; M, mononuclear cells; FAP, fibroblast activation protein; DPP-IV, dipeptidylpeptidase-IV.</p></fn></table-wrap-foot></table-wrap><fig id="fig05" position="float"><label>Figure 5</label><caption><p>Immunohistochemistry in Ewing&#x02019;s sarcoma. Tumour cells, small and round in shape, are negative for fibroblast activation protein (FAP) and dipeptidylpeptidase-IV (DPP-IV). Stromal cells in septal areas are positive for FAP and DPP-IV (marked with a star). Scale bar, 50 &#x003bc;m.</p></caption><graphic xlink:href="his0055-0432-f5"/></fig><fig id="fig04" position="float"><label>Figure 4</label><caption><p>Immunohistochemistry of an osteoblastic area of an osteosarcoma. Fibroblast activation protein (FAP) and dipeptidylpeptidase-IV (DPP-IV) are weakly positive in the osteoblastic area. Scale bar, 25 &#x003bc;m.</p></caption><graphic xlink:href="his0055-0432-f4"/></fig><fig id="fig03" position="float"><label>Figure 3</label><caption><p>Immunohistochemistry of a fibroblastic area of an osteosarcoma. Fibroblast activation protein (FAP) and dipeptidylpeptidase-IV (DPP-IV) are strongly positive. Scale bar, 25 &#x003bc;m.</p></caption><graphic xlink:href="his0055-0432-f3"/></fig><fig id="fig02" position="float"><label>Figure 2</label><caption><p>Immunohistochemistry in low-grade myofibroblastic sarcoma, showing strong positivity for both fibroblast activation protein (FAP) and dipeptidylpeptidase-IV (DPP-IV). IgG1, negative control. Scale bar, 50 &#x003bc;m.</p></caption><graphic xlink:href="his0055-0432-f2"/></fig><p>We then analysed benign tumours to confirm the expression of FAP and DPP-IV. To analyse giant cell tumours, we subdivided the cellular components into giant cells, mononuclear round cells, and spindle-shaped fibroblastic cells. As summarized in <xref ref-type="table" rid="tbl1">Table 1</xref>, all these components of giant cell tumours expressed FAP and DPP-IV (<xref ref-type="fig" rid="fig06">Figure 6</xref>). FAP and DPP-IV were also positive in spindle-shaped tumour cells of one non-ossifying fibroma (<xref ref-type="fig" rid="fig07">Figure 7</xref>), one chondroblastoma, and one desmoid tumour. Osteoclast-like giant cells were positive for FAP and DPP-IV in one osteoid osteoma. Spindle cells expressed FAP and DPP-IV in one of three schwannomas. No tumour cells expressed FAP or DPP-IV in lipoma or elastofibroma.</p><fig id="fig07" position="float"><label>Figure 7</label><caption><p>Immunohistochemistry of a non-ossifying fibroma. Spindle-shaped tumour cells express both fibroblast activation protein (FAP) and dipeptidylpeptidase-IV. Scale bar, 25 &#x003bc;m.</p></caption><graphic xlink:href="his0055-0432-f7"/></fig><fig id="fig06" position="float"><label>Figure 6</label><caption><p>Immunohistochemistry of a giant cell tumour. Fibroblast activation protein (FAP) is expressed in spindle-shaped fibroblastic cells, whereas dipeptidylpeptidase-IV (DPP-IV) is positive in giant cells. Scale bar, 25 &#x003bc;m.</p></caption><graphic xlink:href="his0055-0432-f6"/></fig></sec></sec><sec><title>Discussion</title><p>The present study has clearly shown that fibroblast-like spindle tumour cells strongly express FAP and DPP-IV in low-grade myofibroblastic sarcoma, fibroblastic areas of osteosarcoma, MFH, non-ossifying fibroma, desmoid tumour, and chondroblastoma. The expression pattern is similar to that of activated fibroblasts and/or myofibroblasts in granulation tissue. In contrast, neither FAP nor DPP-IV is expressed in round or oval cells in Ewing&#x02019;s sarcoma or rhabdomyosarcoma.</p><p>Our results demonstrate the following two points. First, expression of FAP and DPP-IV is clearly independent of the malignant potential of the tumours. Second, it is rather related to the histogenesis of the tumour cells, i.e. positive tumour cells are related to activated fibroblasts and/or myofibroblasts. Myofibroblasts are activated fibroblasts that have some of the characteristics of smooth muscle cells, such as contractile properties.<xref ref-type="bibr" rid="b22">22</xref> Eyden has described how tumour cells with complete myofibroblastic differentiation show immunoreactivity for smooth muscle actin, prominent rough endoplasmic reticulum, peripheral smooth-muscle type myofilaments, and fibronexus junctions. It is reasonable therefore that low-grade myofibroblastic sarcomas and fibroblastic areas of osteosarcoma abundantly expressed FAP and DPP-IV. The positivity for FAP and DPP-IV in MFH could be related to the previous demonstration of myofibroblastic differentiation in storiform&#x02013;pleomorphic MFH.<xref ref-type="bibr" rid="b23">23</xref>,<xref ref-type="bibr" rid="b24">24</xref> In sharp contrast, negative tumours in the present study showed other differentiation phenotypes. Chondroblastic and osteoblastic areas of osteosarcoma, both apparently showing different phenotypes, showed weak expression of FAP and DPP-IV. No expression was observed in Ewing&#x02019;s sarcoma or rhabdomyosarcoma, and the two sarcomas are thought to be derived from a different cell lineage: Ewing&#x02019;s sarcoma is considered to be of neuroectodermal origin<xref ref-type="bibr" rid="b25">25</xref> and rhabdomyosarcoma of striated muscle origin. Therefore, our data indicate that FAP and DPP-IV are positive in an activated fibroblast/myofibroblast-like lineage, and negative in other cell lineages, including osteoblastic cells (<xref ref-type="table" rid="tbl1">Table 1</xref>).</p><p>We then considered the relationship to the malignant potential of the tumours, given that both FAP and DPP-IV are serine integral membrane proteinases. This suggests their involvement in cancer invasion and metastasis. However, as shown below, the situation is rather complicated. Cheng <italic>et al.</italic><xref ref-type="bibr" rid="b13">13</xref> indicated that FAP is a tumour promoter, whereas Ramirez-Montagut <italic>et al.</italic><xref ref-type="bibr" rid="b12">12</xref> have described FAP as a tumour suppressor. Ariga <italic>et al.</italic><xref ref-type="bibr" rid="b8">8</xref> reported that the degree of FAP expression in breast cancer stromal cells was associated with a longer survival of patients, and they suggested that FAP may be involved in tissue remodelling of the cancer stroma. The situation for DPP-IV is similar. On the one hand, DPP-IV has been reported to play important roles in metastasis of cancer cells.<xref ref-type="bibr" rid="b14">14</xref> DPP-IV is involved with endothelial cell functions as an adhesion receptor for fibronectin on cancer cells.<xref ref-type="bibr" rid="b20">20</xref> The expression of fibronectin correlates with the ability of cancer cells to bind to DPP-IV and metastasize to the lung.<xref ref-type="bibr" rid="b20">20</xref> The ability of breast cancer cells to capture fibronectin molecules suggests that DPP-IV&#x02013;fibronectin binding may be a relatively common mechanism necessary for lung metastasis.<xref ref-type="bibr" rid="b20">20</xref> On the other hand, DPP-IV may act as a tumour suppressor by regulating levels of E-cadherin in cells through an unknown mechanism.<xref ref-type="bibr" rid="b15">15</xref> Overall, the significance of FAP and DPP-IV in cancer invasion and metastasis is controversial. Our results indicate that both malignant and benign tumours express FAP and DPP-IV. Therefore, the expression of FAP and DPP-IV is irrelevant to the malignant potential of the tumour as far as bone and soft tissue tumours are concerned.</p><p>In addition to the above-mentioned expression in fibroblastic cells, DPP-IV is associated with another notable result of this study. Giant cells in giant cell tumours of bone were positive for DPP-IV. Giant cell tumours were formerly named osteoclastomas, and there has been debate concerning the relationship between giant cells in giant cell tumours and osteoclasts. Osteoclasts in normal bone tissue resemble macrophages in their histogenesis and function,<xref ref-type="bibr" rid="b26">26</xref> and they are positive for DPP-IV.<xref ref-type="bibr" rid="b18">18</xref> Therefore, it is probable that in addition to fibroblastic cells, DPP-IV is also positive in cells of the monocyte&#x02013;macrophage system. DPP-IV expression in reactive giant cells of osteosarcoma further supports this notion.</p><p>In conclusion, both FAP and DPP-IV are expressed in tumour cells that are histogenetically related to activated fibroblasts and/or myofibroblasts, and their expression is not dependent on the malignancy of tumours. Our data suggest that FAP and DPP-IV can be used as markers of activated fibroblasts and/or myofibroblasts. DPP-IV may also be used as a marker of cells in the monocyte&#x02013;macrophage lineage.</p></sec></body><back><sec><title>Competing interests</title><p>None to declare.</p></sec><ack><p>We are grateful to Dr Wen-Tien Chen (Department of Medicine, Stony Brook University, Stony Brook, NY, USA) and to Dr Lloyd J. Old and Dr Matthew Scanlan (Ludwig Institute for Cancer Research, New York, NY, USA), for the kind supply of antibodies used in the present study. Technical assistance by Ms Fumiko Date is greatly appreciated.</p></ack><ref-list><title>References</title><ref id="b1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>JE</given-names></name><name><surname>Lenter</surname><given-names>MC</given-names></name><name><surname>Zimmermann</surname><given-names>RN</given-names></name><name><surname>Garin-Chesa</surname><given-names>P</given-names></name><name><surname>Old</surname><given-names>LJ</given-names></name><name><surname>Rettig</surname><given-names>WJ</given-names></name></person-group><article-title>Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumour stromal fibroblasts</article-title><source>J. Biol. Chem.</source><year>1999</year><volume>274</volume><fpage>36505</fpage><lpage>36512</lpage><pub-id pub-id-type="pmid">10593948</pub-id></element-citation></ref><ref id="b2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pineiro-Sanchez</surname><given-names>ML</given-names></name><name><surname>Goldstein</surname><given-names>LA</given-names></name><name><surname>Dodt</surname><given-names>J</given-names></name><name><surname>Howard</surname><given-names>L</given-names></name><name><surname>Yeh</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>WT</given-names></name></person-group><article-title>Identification of the 170-kDa melanoma membrane-bound gelatinase (seprase) as a serine integral membrane protease</article-title><source>J. Biol. Chem.</source><year>1997</year><volume>272</volume><fpage>7595</fpage><lpage>7601</lpage><pub-id pub-id-type="pmid">9065413</pub-id></element-citation></ref><ref id="b3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rettig</surname><given-names>WJ</given-names></name><name><surname>Chesa</surname><given-names>PG</given-names></name><name><surname>Beresford</surname><given-names>HR</given-names></name><etal/></person-group><article-title>Differential expression of cell surface antigens and glial fibrillary acidic protein in human astrocytoma subsets</article-title><source>Cancer Res.</source><year>1986</year><volume>46</volume><fpage>6406</fpage><lpage>6412</lpage><pub-id pub-id-type="pmid">2877731</pub-id></element-citation></ref><ref id="b4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rettig</surname><given-names>WJ</given-names></name><name><surname>Garin-Chesa</surname><given-names>P</given-names></name><name><surname>Beresford</surname><given-names>HR</given-names></name><name><surname>Oettgen</surname><given-names>HF</given-names></name><name><surname>Melamed</surname><given-names>MR</given-names></name><name><surname>Old</surname><given-names>LJ</given-names></name></person-group><article-title>Cell-surface glycoproteins of human sarcomas: differential expression in normal and malignant tissue and cultured cells</article-title><source>Proc. Natl Acad. Sci. USA</source><year>1988</year><volume>85</volume><fpage>3110</fpage><lpage>3114</lpage><pub-id pub-id-type="pmid">2896356</pub-id></element-citation></ref><ref id="b5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garin-Chesa</surname><given-names>P</given-names></name><name><surname>Old</surname><given-names>LJ</given-names></name><name><surname>Rettig</surname><given-names>WJ</given-names></name></person-group><article-title>Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers</article-title><source>Proc. Natl Acad. Sci. USA</source><year>1990</year><volume>87</volume><fpage>7235</fpage><lpage>7239</lpage><pub-id pub-id-type="pmid">2402505</pub-id></element-citation></ref><ref id="b6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levy</surname><given-names>MT</given-names></name><name><surname>McCaughan</surname><given-names>GW</given-names></name><name><surname>Abbott</surname><given-names>CA</given-names></name><etal/></person-group><article-title>Fibroblast activation protein: a cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodeling interface in human cirrhosis</article-title><source>Hepatology</source><year>1999</year><volume>29</volume><fpage>1768</fpage><lpage>1777</lpage><pub-id pub-id-type="pmid">10347120</pub-id></element-citation></ref><ref id="b7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scanlan</surname><given-names>MJ</given-names></name><name><surname>Raj</surname><given-names>BK</given-names></name><name><surname>Calvo</surname><given-names>B</given-names></name><etal/></person-group><article-title>Molecular cloning of fibroblast activation protein, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers</article-title><source>Proc. Natl Acad. Sci. USA</source><year>1994</year><volume>91</volume><fpage>5657</fpage><lpage>5661</lpage><pub-id pub-id-type="pmid">7911242</pub-id></element-citation></ref><ref id="b8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ariga</surname><given-names>N</given-names></name><name><surname>Sato</surname><given-names>E</given-names></name><name><surname>Ohuchi</surname><given-names>N</given-names></name><name><surname>Nagura</surname><given-names>H</given-names></name><name><surname>Ohtani</surname><given-names>H</given-names></name></person-group><article-title>Stromal expression of fibroblast activation protein/seprase, a cell membrane serine proteinase and gelatinase, is associated with longer survival in patients with invasive ductal carcinoma of breast</article-title><source>Int. J. Cancer</source><year>2001</year><volume>95</volume><fpage>67</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">11241314</pub-id></element-citation></ref><ref id="b9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rettig</surname><given-names>WJ</given-names></name><name><surname>Garin-Chesa</surname><given-names>P</given-names></name><name><surname>Healey</surname><given-names>JH</given-names></name><etal/></person-group><article-title>Regulation and heteromeric structure of the fibroblast activation protein in normal and transformed cells of mesenchymal and neuroectodermal origin</article-title><source>Cancer Res.</source><year>1993</year><volume>53</volume><fpage>3327</fpage><lpage>3335</lpage><pub-id pub-id-type="pmid">8391923</pub-id></element-citation></ref><ref id="b10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>HC</given-names></name><name><surname>Abdel-Ghany</surname><given-names>M</given-names></name><name><surname>Elble</surname><given-names>RC</given-names></name><name><surname>Pauli</surname><given-names>BU</given-names></name></person-group><article-title>Lung endothelial dipeptidyl peptidase IV promotes adhesion and metastasis of rat breast cancer cells via tumour cell surface-associated fibronectin</article-title><source>J. Biol. Chem.</source><year>1998</year><volume>273</volume><fpage>24207</fpage><lpage>24215</lpage><pub-id pub-id-type="pmid">9727044</pub-id></element-citation></ref><ref id="b11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liotta</surname><given-names>LA</given-names></name></person-group><article-title>Tumour invasion and metastases&#x02014;role of the extracellular matrix</article-title><source>Cancer Res.</source><year>1986</year><volume>46</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">2998604</pub-id></element-citation></ref><ref id="b12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramirez-Montagut</surname><given-names>T</given-names></name><name><surname>Blachere</surname><given-names>NE</given-names></name><name><surname>Sviderskaya</surname><given-names>EV</given-names></name><etal/></person-group><article-title>FAP alpha, a surface peptidase expressed during wound healing, is a tumour suppressor</article-title><source>Oncogene</source><year>2004</year><volume>23</volume><fpage>5435</fpage><lpage>5446</lpage><pub-id pub-id-type="pmid">15133496</pub-id></element-citation></ref><ref id="b13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>JD</given-names></name><name><surname>Valianou</surname><given-names>M</given-names></name><name><surname>Canutescu</surname><given-names>AA</given-names></name><etal/></person-group><article-title>Abrogation of fibroblast activation protein enzymatic activity attenuates tumour growth</article-title><source>Mol. Cancer Ther.</source><year>2005</year><volume>4</volume><fpage>351</fpage><lpage>360</lpage><pub-id pub-id-type="pmid">15767544</pub-id></element-citation></ref><ref id="b14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pro</surname><given-names>B</given-names></name><name><surname>Dang</surname><given-names>NH</given-names></name></person-group><article-title>CD26/dipeptidyl peptidase-IV and its role in cancer</article-title><source>Histol. Histopathol.</source><year>2004</year><volume>19</volume><fpage>1345</fpage><lpage>1351</lpage><pub-id pub-id-type="pmid">15375776</pub-id></element-citation></ref><ref id="b15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sulda</surname><given-names>ML</given-names></name><name><surname>Abbott</surname><given-names>CA</given-names></name><name><surname>Hildebrandt</surname><given-names>M</given-names></name></person-group><article-title>DPIV/CD26 and FAP in cancer: a tale of contradictions</article-title><source>Adv. Exp. Med. Biol.</source><year>2006</year><volume>575</volume><fpage>197</fpage><lpage>206</lpage><pub-id pub-id-type="pmid">16700523</pub-id></element-citation></ref><ref id="b16"><label>16</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Mentzel</surname><given-names>T</given-names></name><name><surname>Fletcher</surname><given-names>JA</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Fletcher</surname><given-names>CDM</given-names></name><name><surname>Unni</surname><given-names>KK</given-names></name><name><surname>Mertens</surname><given-names>F</given-names></name></person-group><article-title>Low grade myofibroblastic sarcoma</article-title><source>World Health Organization classification of tumours. Pathology and genetics of tumours of soft tissue and bone</source><year>2002</year><publisher-loc>Lyon</publisher-loc><publisher-name>IARC Press</publisher-name><fpage>94</fpage><lpage>95</lpage></element-citation></ref><ref id="b17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eyden</surname><given-names>B</given-names></name></person-group><article-title>The myofibroblast: a study of normal, reactive and neoplastic tissues, with an emphasis on ultrastructure. Part 2&#x02014;tumours and tumour-like lesions</article-title><source>J. Submicrosc. Cytol. Pathol.</source><year>2005</year><volume>37</volume><fpage>231</fpage><lpage>296</lpage><pub-id pub-id-type="pmid">16612972</pub-id></element-citation></ref><ref id="b18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elleder</surname><given-names>M</given-names></name></person-group><article-title>Enzyme patterns in human endocytotic multinucleate giant cells&#x02014;a histochemical study</article-title><source>Acta Histochem.</source><year>1986</year><volume>79</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">2874682</pub-id></element-citation></ref><ref id="b19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katou</surname><given-names>F</given-names></name><name><surname>Ohtani</surname><given-names>H</given-names></name><name><surname>Nakayama</surname><given-names>T</given-names></name><etal/></person-group><article-title>Macrophage-derived chemokine (MDC/CCL22) and CCR4 are involved in the formation of T lymphocyte-dendritic cell clusters in human inflamed skin and secondary lymphoid tissue</article-title><source>Am. J. Pathol.</source><year>2001</year><volume>158</volume><fpage>1263</fpage><lpage>1270</lpage><pub-id pub-id-type="pmid">11290544</pub-id></element-citation></ref><ref id="b20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldstein</surname><given-names>LA</given-names></name><name><surname>Ghersi</surname><given-names>G</given-names></name><name><surname>Pineiro-Sanchez</surname><given-names>ML</given-names></name><etal/></person-group><article-title>Molecular cloning of seprase: a serine integral membrane protease from human melanoma</article-title><source>Biochim. Biophys. Acta</source><year>1997</year><volume>1361</volume><fpage>11</fpage><lpage>19</lpage><pub-id pub-id-type="pmid">9247085</pub-id></element-citation></ref><ref id="b21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacobs</surname><given-names>TW</given-names></name><name><surname>Gown</surname><given-names>AM</given-names></name><name><surname>Yaziji</surname><given-names>H</given-names></name><name><surname>Barnes</surname><given-names>MJ</given-names></name><name><surname>Schnitt</surname><given-names>SJ</given-names></name></person-group><article-title>Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system</article-title><source>J. Clin. Oncol.</source><year>1999</year><volume>17</volume><fpage>1983</fpage><lpage>1987</lpage><pub-id pub-id-type="pmid">10561248</pub-id></element-citation></ref><ref id="b22"><label>22</label><element-citation publication-type="book"><source>The American Heritage Stedman&#x02019;s Medical Dictionary</source><year>2004</year><edition>2nd edn</edition><publisher-loc>Boston</publisher-loc><publisher-name>Houghton Mifflin</publisher-name></element-citation></ref><ref id="b23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montgomery</surname><given-names>E</given-names></name></person-group><article-title>Myofibroblastic differentiation in malignant fibrous histiocytoma (pleomorphic myofibrosarcoma): a clinicopathological study</article-title><source>Histopathology</source><year>2001</year><volume>38</volume><fpage>499</fpage><lpage>509</lpage><pub-id pub-id-type="pmid">11422493</pub-id></element-citation></ref><ref id="b24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fukuda</surname><given-names>T</given-names></name><name><surname>Tsuneyoshi</surname><given-names>M</given-names></name><name><surname>Enjoji</surname><given-names>M</given-names></name></person-group><article-title>Malignant fibrous histiocytoma of soft parts: an ultrastructural quantitative study</article-title><source>Ultrastruct. Pathol.</source><year>1988</year><volume>12</volume><fpage>117</fpage><lpage>129</lpage><pub-id pub-id-type="pmid">2832988</pub-id></element-citation></ref><ref id="b25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elizabeth</surname><given-names>RL</given-names></name><name><surname>Lim</surname><given-names>JF</given-names></name><name><surname>Wen</surname><given-names>Tao</given-names></name><etal/></person-group><article-title>The Ewing tumour family of peripheral primitive neuroectodermal tumours expresses human gastrin-releasing peptide</article-title><source>Cancer Res.</source><year>1998</year><volume>58</volume><fpage>2469</fpage><lpage>2476</lpage><pub-id pub-id-type="pmid">9622091</pub-id></element-citation></ref><ref id="b26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyamoto</surname><given-names>N</given-names></name><name><surname>Higuchi</surname><given-names>Y</given-names></name><name><surname>Tajima</surname><given-names>M</given-names></name><etal/></person-group><article-title>Spindle-shaped cells derived from giant-cell tumour of bone support differentiation of blood monocytes to osteoclast-like cells</article-title><source>J. Orthop. Res.</source><year>2000</year><volume>18</volume><fpage>647</fpage><lpage>654</lpage><pub-id pub-id-type="pmid">11052502</pub-id></element-citation></ref></ref-list><glossary><def-list><title>Abbreviations:</title><def-item><term>DPP-IV</term><def><p>dipeptidylpeptidase-IV</p></def></def-item><def-item><term>FAP</term><def><p>fibroblast activation protein</p></def></def-item><def-item><term>MFH</term><def><p>malignant fibrous histiocytoma</p></def></def-item></def-list></glossary></back></article>